Abiopharma

🔍 Carroll Patrick Harrison (Executive)

Company: Hims & Hers Health, Inc. (HIMS)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 3,656 shares of Class A Common Stock (Direct)
  Date: 2026-06-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 187,536.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 435 shares of Class A Common Stock (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 187,971.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 3,656 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-11 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 435 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-15 | Code: M | Exercise: 2026-06-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F3

Footnotes:

• F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026.
• F2: Includes 1,440 shares acquired on May 20, 2026, under the Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan.
• F3: The RSUs were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy, in lieu of the director retainer fee for the first quarter of 2026. The number of RSUs granted was calculated by dividing the foregone cash fees of $10,000 by the grant price of $22.98. The RSUs will vest in full on the Company's next quarterly vesting date.
• F4: The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU.